Primary Biliary Cholangitis Market: Industry Size, Share Trends, Growth, Demand, Opportunities and Forecast

dbmr2145

posted on 8 months ago — updated on 3 seconds ago

46
views

Data Bridge Market Research analyses that the primary biliary cholangitis market was valued at USD 784.81 million in 2021 and is expected to reach USD 1,744.47 million by 2029, registering a CAGR of 10.50% during the forecast period of 2022 to 2029

Primary Biliary Cholangitis Market: Industry Size, Share Trends, Growth, Demand, Opportunities and Forecast

An important Primary Biliary Cholangitis Market research report is produced by taking into account every requirement that organizations need to meet in order to expand successfully. This market report forecasts the market size based on data on major retailer sales, industry growth by upstream and downstream factors, industry advancement, major players, market segments, and application. When creating the reliable Primary Biliary Cholangitis Market study, the goals of the marketing research are taken into consideration. A market segmentation analysis is conducted taking into account the currencies, pricing, years taken into consideration, geographic scope, and markets covered.

Explore Further Details about This Research Primary Biliary Cholangitis Market Report https://www.databridgemarketresearch.com/reports/global-primary-biliary-cholangitis-market

Primary biliary cirrhosis is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are symptoms of primary biliary cirrhosis, which can progress to hepatomegaly and hyperpigmentation splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.

Market Definition

Primary biliary cholangitis, also known as primary biliary cirrhosis, is a chronic liver condition in which the bile ducts are gradually damaged. PBC has no known treatment. To control symptoms and reduce the progression of PBC, doctors prescribe medication. Ursodiol aids in the removal of bile from the liver. In many cases, this medication improves liver function and slows the course of liver disease. If ursodeoxycholic acid (UDCA) is ineffective or cannot be tolerated, obeticholic acid is used alone or in combination with it.

Drivers

Increasing prevalence of primary biliary cholangitis

The rising prevalence of primary biliary cholangitis across the globe is estimated to enhance the market's growth. Primary biliary cholangitis (PBC) is an uncommon disease that causes a persistent, progressive liver disorder. It primarily affects women and usually strikes between the ages of 30 and 60. The tiny bile duct in the liver is usually affected by PBC. Primary biliary cholangitis is split into four phases: stage 1 (no scarring) to stage 4 (cirrhosis). A mix of causes, including autoimmune, genetic, and environmental factors, can cause PBC.

Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of primary biliary cholangitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Recent Development

In May 2022, Intercept Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for treating patients suffering from primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid.

Global Primary Biliary Cholangitis Market Scope

The primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

Liver Transplantation
Drug Therapy
Ursodeoxycholic acid (UDCA)
Obeticholic acid
Fibrates
Budesonide
Others

Diagnosis

Imaging Tests
Magnetic resonance elastography (MRE)
Magnetic resonance cholangiopancreatography (MRCP)
Ultrasound
FibroScan
Blood Tests
Cholesterol test
Antibody tests
Liver tests
Others

Route of Administration

Oral
Parenteral
Others

End-Users

Hospitals
Specialty Clinics
Homecare
Others

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Some of the major players operating in the primary biliary cholangitis market are:

Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Ireland)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Merck & Co., Inc. (U.S.)
Allergan (Ireland)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Bristol-Myers Squibb Company (U.S.)
Bayer AG (Germany)
Boehringer Ingelheim International GmbH. (Germany)
Reddy’s Laboratories Ltd. (India)
Gilead Sciences, Inc. (U.S.)
Amgen Inc. (U.S.)
Eli Lilly and Company (U.S.)
AbbVie Inc. (U.S.)
Lupin (India)
Allergan (Ireland)

Key Offerings:

Past Market Size and Competitive Landscape (2018 to 2022)
Past Pricing and price curve by region (2018 to 2022)
Market Size, Share, Size & Forecast by different segment | 2023−2029
Primary Biliary Cholangitis MarketDynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by Region
Market Segmentation – A detailed analysis by segment with their sub-segments and Region
Competitive Landscape – Profiles of selected key players by region from a strategic perspective
Competitive landscape – Market Leaders, Market Followers, Regional player
Competitive benchmarking of key players by region
PESTLE Analysis
PORTER’s analysis
Value chain and supply chain analysis
Legal Aspects of Business by Region
Lucrative business opportunities with SWOT analysis
Recommendations